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A STUDY ON DIRECT ANTITUMOR 
ACTIVITY OF BROPIRIMINE (ORAL 
INTERFERON INDUCER) FOR RENAL 
CELL CARCINOMA 
Tetsuro Oni~hi and Toyohei Machida 
From the Department of Urology, Jikei University School of Medicine 
Aryl pyrimidinones, including bropirimine, exert anti-tumor activity through the induction of 
interferon (IFN)-alpha. Herein, the direct anti-tumor effect of bropirimine on 17 renal cell carci-
noma (RCC) surgically obtained was examined using an organ culture system closely resembling 
the in vivo state, and also using the heterotransplanted nude mouse system. The findings obtained 
using the organ culture system showed that bropirimine inhibited 3H-thymidine uptake significantly 
in 15 of the 17 RCC (88.2%) compared with the control. Furthermore, the 3H-thymidine uptake 
was dose-dependently inhibited in 3 of the 17 tumors (17.6%). The oral administration of bropi-
rimine against RCC heterotransplanted in nude mice URC 901: an erythropoietin-producing strain) 
tended to inhibit tumor growth dose-dependently, but not significantly (mean tumor weight ratio: 
TIC ratio: over 43%, degeneration degree of tumor: incomplete). However, the production of 
erythropoietin from the JRC 901 was significantly inhibited. These findings suggest that bropiri-
mine has a direct anti-tumor activity, without the mediation of IFN-alpha induction, against human 
renal cell carcinoma. 
(Acta Urol. Jpn. 40: 195-200, 1994) 
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INTRODUCTION 
Bropirimine (U-54, 461S) is a derivative 
of aryl pyrimidinones developed by 
the Upjohn Company of U.S.A. It pro-
duces cytokines including interferon-alpha 
(IFN-alpha) after administration in ani-
mals or humansl 2). In Japan, bropirimine 
is currently being tested as a new drug 
which provides anti-tumor activity through 
the induction of IFN-alpha in phase II 
study for patients with renal cell carcino-
ma (RCC) and with bladder cancer. In 
this study, we examined the direct anti-tu-
mor activity of bropirimine using renal 
cell carcinoma obtained from surgery. 
MATERlALS AND METHODS 
I) Materials 
We examined 17 RCC tumors derived 
from operations at Jikei University Hospi-
tal between January and September 1992. 
All patients received nephrectomy except 
for one who received resection of metasta-
sized tumor in the retroperitoneal cavity. 
Over 70% of the patients had low stage 
and low grade tumors. 
2) Methods 
a) Organ culture system: Cultures were 
conducted according to the method of 
Hoffman et al.3). After placing the sliced 
collagen gel matrix (2 x I cm square: 
spongostan) in a 6-well plate, we added 4 
ml of Dulbecco's modified eagle medium 
(MEM) containing 20% faetal calf serum 
(FCS) and allowed it to stand for 6 
hours. The tumor was cut into 2 x 2 mm 
pieces, and placed on the spongostan. 
Each experimental group consisted of 14 tu-
mors. After 7 days of incubation with CO 2 
at 3rC, the anti-tumor efficacy was evalu-
ated by comparison of the 3H-thymidine 
uptake between treated tumors and the 
control. 
Bropirimine was used at two doses, i.e., 
24.58 and 49.16 p.g/ml based upon the peak 
blood level of bropirimine determined in 
the phase I trial (Cmax.: 51.94 ± 17.5 p.g/ 
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ml)2). In the control group, physiological 
saline was added to the medium. 
b) Nude mouse system: To establish the 
RCC tumor heterotransplanted in nude 
mice, we inoculated the 17 tumors which 
had been tested in the in-vivo-like culture 
system to nude mice. One of the 17 tu-
mors proved serially heterotransplantable 
in nude mice ORC 901) (Fig. la). 
Furthermore, the JRC 901 tumor not only 
showed positive staining with the anti-Epo 
antibody (Fig. Ib), but also produced e-
rythropoietin (Epo) at a high level after the 
inoculation of the tumor. 
Fig. lao Histological feature of JRC 901 (H & 
E staining, x 100) JRC 901 tumor 
consisted of granular cell type, alveolar 
pattern and grade II renal cell carci-
noma. 
Fig. lb. Immunohistochemical staining feature 
of anti-Epo antibody (x 100). Positive 
reaction was observed within the cyto-
plasms of all JRC 901 tumors. 
The JRC 901 tumor was inoculated sub-
cutaneously into both lateral abdomens of 
the mice, and after the tumor had grown 
to the logarithmic phase (5 weeks after 
inoculation), bropirimine was administered 
orally. Two doses were tested (500 mg/kg 
and 1,000 mg/kg) based upon the basic data 
On blood drug levels at which IFN-alpha 
could be ind uced4). Bropirimine was 
dissolved in 0.5% sodium carboxylmethyl 
cellulose (CMC) , the solution was adjusted 
to yield a prescribed drug concentration 
(500mg/kg or 1,000 mg/kg), and the volume 
of the single dose was 0.15 ml/body (25 
g) . Bropirimine was administered every 4 
days orally for a total of 8 times. In the 
control mice, 0.15 ml physiological saline 
was orally administered similarly. 
The mice used in this study were male 
BALB/C nu e +) /nu (+), mice, 6-8 weeks 
of age (Clea Japan). Five mice were used 
in the treated group (control group consis-
ted of 8 mice), and maintained in a specif-
ic-pathogen-free (SPF) environment in 
the Laboratory Animal Center of our uni-
versity. 
c) Evaluation of efficacy: Anti-tumor activ-
ity was assessed according to the NCI's 
protocol (Battle Columbus Laboratory 
protocoI5»). After the inoculation of the 
tumor, its short (S) and long (L) diame-
ters were measured and from the volume 
(V mg) = Lx S2/2 according to the sphe-
roidal theory, the relative mean tumor 
weight ratio (T /C ratio) was determined 
as follows. 
The equation for the calculation of T /C 
. Tn/TO 
ratiO=Cn/CO x 100 e%) 
Tn: tumor weight in the therapeutic group 
on day n, 
TO: tumor weight in the therapeutic group 
on day 0, 
Cn: tumor weight in the control group 
on day n, 
CO: tumor weight in the control group on 
day 0, 
When the calculated T /C ratio for any 
group was 42% or lower, the response was 
defined as positive; when it was 43% Or 
higher, the treatment was judged to be 
ineffective. 
Simultaneously, a histological evaluation 
was made according to the classification of 
Shimosato et aI. (grade I: no degeneration 
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grade IIa: partial degeneration; under 50 
%, grade lIb: partial degeneration; over 
50%, but viable cells still remaining, grade 
III: no viable cells are detected, grade 
IV: no viable cells are detected with the 
replacement of fibroblasts or other reactive 
histological changes after all tumor cells 
were killed6l). Degeneration equal to or 
higher than grade III, wherein no viable 
tumor cells are observed, was considered 
an indication of histological effectiveness. 
Furthermore, since the jRC 901 tumor 
produced Epo, especially 5 weeks after 
inoculation, the inhibition of production 
of Epo was also examined to evaluate the 
efficacy of bropirimine. 
d) Analysis of Epo level: Serum specimens 
were collected from the tumor-bearing 
mice every week after the tumor were incu-
lated in the two treated groups Eall mice) 
and the control group (5 of B mice), and 
stored at _BODC. At analysis, the serum 
specimens were thawed and 50 mel sera 
were used in duplicate for the radio-
immunoa,ssay conducted by SRL Company 
Ltd., japan. Robson's7) staging system of 
RCC and Bannayan's four-stepS) grading 
system were used. Student's t-test was 
used to determine the significance of 
differences among the tested groups. 
RESULTS 
1) Organ culture system 
3H-thymidine uptake was significantly in-
hibited in 15 of the 17 RCC tumors (BB.2 
%) after the treatment with bropirimine 
at either high or low dose or both com-
pared with the control (0.01 <P<0.05). In 
3 of these 17 tumors (17.6%), the inhibi-
tion of 3H-thymidine was dose-dependent, 
but no dose-dependency was observed in 
9 tumors (52.9%). One tumor responded 
to the high dose (5.9%), two (I1.B%) to 
the low dose and another two (I1.B%) to 
neither of the doses. 
2) Effects using jRC 901 strain 
Of the 3 tumors in which 3H-thymidine 
uptake was inhibited by bropirimine in the 
organ culture system dose-dependently 
(Fig. 2), I tumor was serially heterotrans 
plantable in nude mice ORC 901) (Fig. 
la). We examined the anti-tumor activity 
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Fig. 2. Three tumors where 3R·thymidine uptake was 
significantly suppressed dose-dependently by 
treatment with Bropirimine. Case 1 represents a 
tumor which was heterotransplantable in nude 
mice ORC 901). (Case I: 24.56 pg/dl vs 
control, 49.16 pg/dl vs control, 24.56 pg/dl vs 
49.16 pg/dl: 0<P<0.02, Case 2: 24.15 pg/dl vs 
control; O.02<P 0.05, 49.16 pg/dl vs control; 
0<0.002, 24.56pg/dl vs 49.16 pg/dl; o<P 0.02, 
Case :3: 24. 58 pg/dl vs control; 0.002<P<0.02, 
49.16 pg/dl vs control; 0<P<0.002, 24.58 pg/dl 
vs 49.16 pg/dl; 0.002<P<0.02). (DPM: Disin-
tegration per minutes) 
198 Acta Ural. Jpn. Vol. 40, No.3, 1994 





, ' .. ,f--11 ,000 mg/kg 
"-f •• ,f •• 0 
100 
O~~~~~-r-r~~~~r-~~~------
o 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 (weeks) 
Weeks after tumour inoculation 
Fig. 3, Anti·tumor efficacy of Bropirimine against JRC 
901 strain heterotr21nsplanted to nude mice. 
Dose·dependent suppression of tumor growth 
was noted following oral administration of bropi-
rimine. However, the rate of T/C was not signif-
icant because of its rate was over 42% (500 
ng/kg: 91.8%, 1,000 mg/kg: 67.7%). (each growth 
point was mean value with standard deviations.) 
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Fig. 4. Time-course changes in serum level of erythropoietin after 
oral administration of bropirimine. A significant suppres-
sion of erythropoietin production was noted 3 weeks after 
the start of treatment with bropirimine (1,000 mg/kg) (3 
weeks after the start of treatment to 4 weeks: P<0.05, after 
5 weeks: 0.002<P<0.005). 
of bropirimine using the ]RC 901 strain. 
Fig. 3 shows the growth curves for the 
treatment groups and the control. 
from the histological viewpoint. 
Bropirimine at the dose of 1,000 mg/kg 
inhibited tumor proliferation significantly, 
and compared with the control, it reduced 
the mean tumor weight from the 3rd week 
after the treatment was started (Fig. 3). 
However, the T/C ratio was 67.7%, indi-
cating that the treatment was ineffective. 
As to the degree of histological degenera-
tion, viable tumor cells remained in 39% 
of the area (grade lIb). Therefore, bro~ 
pirimine was ineffective from the histoI-
Bropirimine at the dose of 500 mg/kg 
inhibited tumor proliferation, but not 
significantly compared with the control. 
The TIC ratio was 91.8%, indicating no 
posItive response. The degree of histol-
ogical degeneration was grade IIa with 
viable tumor cells remaining in over 50% 
of the total tumor area. Therefore, this 
dose of bropirimine was also ineffective 
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ogical viewpoint. 
After three weeks of treatment with bro-
pirimine at a dose of 500 mg/kg, the serum 
concentration of Epo tended to be lower 
than that in the control group. Further-
more, the production of Epo after three 
weeks of treatment with 1,000mg/kg was 
significantly suppressed (Fig. 4). Thus, by 
inhibiting the production of Epo, the ad-
ministration of bropirimine was effective 
against the jRC 901 tumor. 
DISCUSSION 
Chemotherapy and radiotherapy have 
been applied in the treatment of patients 
with advanced RCC, but these treatment 
modalities have been far from encouraging 
so far9IO). With new clinical application 
of cytokines including IFNs due mainly 
to the development of techniques made 
possible by genetic recombination in the 
1980s, various kinds of cytokine therapy 
have been applied on many patients with 
advanced cancer. Although satisfactory 
results have not b:een obtained lll . IFN 
clearly produces a higher response rate in 
the treatment of RCC than the convention-
al treatment modalities mentioned above. 
Therefore, cytokine therapy including IFN 
is promISIng in the treatmant of patients 
with advanced RCC. Bropirimine is a 
drug developed based on a totally new 
concept. It produces various effects includ-
ing the induction of endogenous IFN-
alpha, activation of natural killer cells 
(NK cells), activation of macrophages, 
induction of interleukin-I (IL-I) and 
enhancement of antigen-antibody interac-
tion in animal experiments ll In japan, 
phase II trials targeting RCC and bladder 
tumors are underway on the basis of the 
results of the phase I trials. In addition 
to inducing endogenous cytokines, bropi-
rimine is excreted in intact form in the 
urine at high concentrations2). 
Encouraged by these pharmacological 
properties, we examined whether bropiri-
mine had a direct anti-tumor activity 
against RCC. In the experiment utilizing 
the organ culture system where bropiri-
mine was brought in direct cOntact with 
tumor tissues, 3H-thymidine uptake was 
significantly reduced, which indicated the 
suppression of DNA synthesis of the tu-
mor cells, in 88.2% of all treated tumors. 
Therefore, these findings suggested that 
bropirimine had direct anti-tumor activity 
against RCC. Furthermore, orally admin-
istered bropirimine induced not only an 
anti-proliferative action against the jRC 
901 strain, but also suppressed its erythro-
poietin production heterotransplanted in 
nude mice. These findings also indicated 
the presence of direct anti-tumor activity 
against RCC, because even if endogenous 
mouse IFN-alpha was produced by the 
administration of bropirimine, mouse IFN 
had no anti-tumor activity against human 
tumors. 
The findings of experiment using tumor-
bearing nude mice suggested that bropiri-
mine could not totally eliminate the xeno-
grafted tumors. Therefore, the develop-
ment of more effective treatment modali 
-ties with enhanced anti-tumor activity of 
bropirimine, such as the combination of 
bro,pirimine with chemotherapy, IL-2 or 
radiation is awaited 12). Furthermore, in 
addition to the direct anti-tumor activity 
against RCC which shown here, the excre-
tion of intact bropirimine at high concen-
trations in urine, as reported in the phase 
I study2), appears to support the high effi-
cacy of bropirimine against superficial 
bladder cancer in the clinical setting I3), 
which will be an interesting subject for 
future study. 
REFERENCES 
I) Wierenga W: Antiviral and other bioactivi-
ties of pyrimidinones. Pharmacol Ther 30: 
67-80, 1985 
2) Wakui A, Ariyoshi Y, Furue H, et al.: Phase 
I clinical study of bropirimine. Biotherapy 
5: 202, 1991 
3) Hoffman RM, Connors KM, Meerson-Mono-
sov AZ, et al.: A general native-state me-
thod for determination of proliferation 
capacity of human normal and tumor tissues 
in vitro. Natl Acad Sci USA 86: 2013-
2017, 1989 
4) Li LH, Branstetter DG, Postmus Rj, et al.; 
Therapeutic evaluation of bropirimine a-
gainst two human tumor xenografts. Proc 
 9nn Acta Urol. Jpn. Vol. 40, No. 3, 1994
  Am Assoc Cancer Res 31: 280, 1990 
5) Ovejera AA, Houchens PP and Barker AD: 
  Chemotherapy of human tumor xenografts 
  in genetically athymic mice. Ann Clin Lab 
  Sci 8: 50-56, 1978 
6) Shimosato Y, Oboshi S and Baba K: Histol-
  ogical evaluation of effects of radiotherapy 
  and chemotherapy for carcinomas. Jpn J 
  Clin Oncol 1: 19-35, 1971 
7) Robson CJ, Churchill BM and Anderson W: 
  The results of radical nephrectomy for rena 
  1 cell carcinoma. J Urol 101: 297-301, 1969 
8) Bannayan GA and Lamm  DL: Renal cell 
  tumors. Pathol Annu 15:  271-308, 1980
9) Onishi T,  Iizuka N, Suzuki M, et  al.. Clini-
  cal study on the effects of chemotherapy as 
  treatment of renal cell carcinoma. J Jpn 
  Soc Cancer Ther 23: 43-49, 1988
10) Forman  JD: The role of radiation therapy 
   in the management of carcinoma of the 
   kidney. Semin Urol 3: 195-198, 1989 
11) Horoszewicz JS and Murphy GP: An assess-
   ment of the current use of human interfer-
   ons in the therapy of urological cancers. J 
  Urol 142: 1173-1179, 1989 
12) Onishi T, Machida T,  Iizuka IN,  et al.: 
   Effect of combination treatment with inter-
   leukin-2 and radiation for murine renal cell 
   carcinoma. Cancer J 5: 230-234, 1992 
13) Sarosdy MF, Lamm DL, Williams RD, et 
   al.: Phase  1 trial of oral bropirimine in su-
   perficial bladder cancer. J Urol 147: 31-33,  
1  0Q9
 'Received on June 21, 1993 
 Accepted on November 11,  1993
和文抄録
Bropirimine(経ロイ ンター フェ ロン産生 薬剤)の 腎細胞癌
に対 す る直接 的抗腫 瘍効果 に 関す る検 討
東京慈恵会医科大学泌尿器科学教室(主任:町田豊平教授)
大西 哲郎,町 田 豊平
腎 細 胞癌 症 例17例の腎摘 時 採取 した 腫 瘍 を用 い て器
官 培 養 法,な らび に ヌ ー ドマ ウス移 植 継 代 可能 株 とな
った1株 を用 い て,bropirimineの直接 的抗 腫 瘍 効
果 に 関 して検 討 した.そ の結 果,器 官 培 養 法 では,17
例 中15例(8&2%)が 対 照 群 に 比較 して3H-thymi-
dineuptakeが有 意 に 抑制 され,そ の うち3例(17.6
%)はbropirimineの濃 度 依存 性 に3H-thymidine
のuptakeが抑制 され た.さ らに,ヌ ー ドマ ウ ス可移
植 性(erythropoietin;Epo産生 株)と な った1株
JRcgol)に 対 す るbropirimineの経 口投 与 で は,
・ropirimineの濃 度依 存 性 に 腫 瘍 増 殖 が抑 制 さ れ た
β,対 照 群 間 に有 意 差 は な く,か つ 組 織 学 的 に もvia
bleな腫瘍 細 胞 の 完 全消 失 は え ら れ なか った.し か
,,JRC901株 のEpo産 生量 は,対 照 群 に 比 較 し
:有意 に 抑 制 さ れ た.以 上 の 結 果,bropirimineは
耳細 胞 癌 に 対 し直 接 的 抗 腫瘍 活 性 を 有 す る こ とが 明 ら
)・とな った.
(泌尿 紀要40:195-200,1994)
